269 related articles for article (PubMed ID: 21362439)
1. Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels.
Xia M; Shahane SA; Huang R; Titus SA; Shum E; Zhao Y; Southall N; Zheng W; Witt KL; Tice RR; Austin CP
Toxicol Appl Pharmacol; 2011 May; 252(3):250-8. PubMed ID: 21362439
[TBL] [Abstract][Full Text] [Related]
2. A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.
Titus SA; Beacham D; Shahane SA; Southall N; Xia M; Huang R; Hooten E; Zhao Y; Shou L; Austin CP; Zheng W
Anal Biochem; 2009 Nov; 394(1):30-8. PubMed ID: 19583963
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of HERG potassium channel inhibition by tetra-n-octylammonium bromide and benzethonium chloride.
Long Y; Lin Z; Xia M; Zheng W; Li Z
Toxicol Appl Pharmacol; 2013 Mar; 267(2):155-66. PubMed ID: 23313619
[TBL] [Abstract][Full Text] [Related]
4. Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.
Huang XP; Mangano T; Hufeisen S; Setola V; Roth BL
Assay Drug Dev Technol; 2010 Dec; 8(6):727-42. PubMed ID: 21158687
[TBL] [Abstract][Full Text] [Related]
5. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.
Schmalhofer WA; Swensen AM; Thomas BS; Felix JP; Haedo RJ; Solly K; Kiss L; Kaczorowski GJ; Garcia ML
Assay Drug Dev Technol; 2010 Dec; 8(6):714-26. PubMed ID: 21158686
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HERG potassium channels by domiphen bromide and didecyl dimethylammonium bromide.
Long Y; Chen W; Lin Z; Sun H; Xia M; Zheng W; Li Z
Eur J Pharmacol; 2014 Aug; 737():202-9. PubMed ID: 24846011
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.
Potet F; Lorinc AN; Chaigne S; Hopkins CR; Venkataraman R; Stepanovic SZ; Lewis LM; Days E; Sidorov VY; Engers DW; Zou B; Afshartous D; George AL; Campbell CM; Balser JR; Li M; Baudenbacher FJ; Lindsley CW; Weaver CD; Kupershmidt S
J Biol Chem; 2012 Nov; 287(47):39613-25. PubMed ID: 23033485
[TBL] [Abstract][Full Text] [Related]
8. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.
Ficker E; Obejero-Paz CA; Zhao S; Brown AM
J Biol Chem; 2002 Feb; 277(7):4989-98. PubMed ID: 11741928
[TBL] [Abstract][Full Text] [Related]
9. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
10. Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux.
Bridal TR; Margulis M; Wang X; Donio M; Sorota S
Assay Drug Dev Technol; 2010 Dec; 8(6):755-65. PubMed ID: 20658944
[TBL] [Abstract][Full Text] [Related]
11. Propofol inhibits hERG K
Han SN; Jing Y; Yang LL; Zhang Z; Zhang LR
Eur J Pharmacol; 2016 Nov; 791():168-178. PubMed ID: 27575519
[TBL] [Abstract][Full Text] [Related]
12. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
Qu Y; Gao B; Fang M; Vargas HM
J Pharmacol Toxicol Methods; 2013; 68(1):74-81. PubMed ID: 23518063
[TBL] [Abstract][Full Text] [Related]
13. Effect of azelastine on cardiac repolarization of guinea-pig cardiomyocytes, hERG K⁺ channel, and human L-type and T-type Ca²⁺ channel.
Park MH; Lee SH; Chu DH; Won KH; Choi BH; Choe H; Jo SH
J Pharmacol Sci; 2013 Sep; 123(1):67-77. PubMed ID: 24005046
[TBL] [Abstract][Full Text] [Related]
14. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
Ridley JM; Milnes JT; Hancox JC; Witchel HJ
J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
[TBL] [Abstract][Full Text] [Related]
15. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
16. hERG channel blockade by externally applied quaternary ammonium derivatives.
Choi KH; Song C; Shin D; Park S
Biochim Biophys Acta; 2011 Jun; 1808(6):1560-6. PubMed ID: 21320466
[TBL] [Abstract][Full Text] [Related]
17. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
18. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in computational prediction of HERG blockage.
Wang S; Li Y; Xu L; Li D; Hou T
Curr Top Med Chem; 2013; 13(11):1317-26. PubMed ID: 23675938
[TBL] [Abstract][Full Text] [Related]
20. Molecular Insights into hERG Potassium Channel Blockade by Lubeluzole.
Gualdani R; Cavalluzzi MM; Tadini-Buoninsegni F; Convertino M; Gailly P; Stary-Weinzinger A; Lentini G
Cell Physiol Biochem; 2018; 45(6):2233-2245. PubMed ID: 29550817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]